Charles River Laboratories International Inc
CRL195.985USD
+0.765+0.39%
Cierre 12/17, 16:00（ET）Cotizaciones retrasadas 15 min
9.65BCap. mercado
PérdidaP/E TTM
Más Datos de Charles River Laboratories International Inc Compañía
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Información de Charles River Laboratories International Inc
Símbolo de cotizaciónCRL
Nombre de la empresaCharles River Laboratories International Inc
Fecha de salida a bolsaJun 23, 2000
Director ejecutivoFoster (James C)
Número de empleados18600
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 23
Dirección251 Ballardvale St
CiudadWILMINGTON
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal01887
Teléfono17812226000
Sitio Webhttps://www.criver.com/
Símbolo de cotizaciónCRL
Fecha de salida a bolsaJun 23, 2000
Director ejecutivoFoster (James C)
Ejecutivos de Charles River Laboratories International Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. James C. Foster
Mr. James C. Foster
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
267.96K
+6.88%
Ms. Birgit Girshick
Ms. Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Chief Operating Officer, Corporate Executive Vice President
57.72K
+24.38%
Ms. Victoria L. (Vicky) Creamer
Ms. Victoria L. (Vicky) Creamer
Corporate Executive Vice President, Chief People Officer
Corporate Executive Vice President, Chief People Officer
17.89K
+48.67%
Ms. Shannon M. Parisotto
Ms. Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment
Management
Corporate Executive Vice President - Discovery and Safety Assessment
Management
12.88K
+69.56%
Mr. Joseph W. LaPlume
Mr. Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Corporate Executive Vice President - Corporate Development and Strategy
12.48K
-8.77%
Ms. Virginia M. (Gina) Wilson, CPA
Ms. Virginia M. (Gina) Wilson, CPA
Independent Director
Independent Director
4.91K
+23.86%
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Independent Director
Independent Director
3.96K
+31.35%
Ms. Reshema Kemps-Polanco
Ms. Reshema Kemps-Polanco
Independent Director
Independent Director
2.59K
+155.42%
Dr. Craig B. Thompson, M.D.
Dr. Craig B. Thompson, M.D.
Independent Director
Independent Director
2.41K
+64.49%
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
Independent Director
Independent Director
946.00
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. James C. Foster
Mr. James C. Foster
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
267.96K
+6.88%
Ms. Birgit Girshick
Ms. Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Chief Operating Officer, Corporate Executive Vice President
57.72K
+24.38%
Ms. Victoria L. (Vicky) Creamer
Ms. Victoria L. (Vicky) Creamer
Corporate Executive Vice President, Chief People Officer
Corporate Executive Vice President, Chief People Officer
17.89K
+48.67%
Ms. Shannon M. Parisotto
Ms. Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment
Management
Corporate Executive Vice President - Discovery and Safety Assessment
Management
12.88K
+69.56%
Mr. Joseph W. LaPlume
Mr. Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Corporate Executive Vice President - Corporate Development and Strategy
12.48K
-8.77%
Ms. Virginia M. (Gina) Wilson, CPA
Ms. Virginia M. (Gina) Wilson, CPA
Independent Director
Independent Director
4.91K
+23.86%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
Por negocioUSD
Nombre
Ganancia
Proporción
DSA
618.03M
59.88%
RMS
213.27M
20.66%
Manufacturing
200.84M
19.46%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
549.86M
53.27%
Europe
281.86M
27.31%
Canada
135.59M
13.14%
Asia Pacific (Region)
54.50M
5.28%
Other
10.33M
1.00%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
DSA
618.03M
59.88%
RMS
213.27M
20.66%
Manufacturing
200.84M
19.46%
Estadísticas de accionistas
Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
11.84%
Wellington Management Company, LLP
6.48%
BlackRock Institutional Trust Company, N.A.
5.73%
Allspring Global Investments, LLC
4.43%
State Street Investment Management (US)
3.72%
Otro
67.80%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
11.84%
Wellington Management Company, LLP
6.48%
BlackRock Institutional Trust Company, N.A.
5.73%
Allspring Global Investments, LLC
4.43%
State Street Investment Management (US)
3.72%
Otro
67.80%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
44.49%
Investment Advisor
44.48%
Hedge Fund
7.70%
Research Firm
4.24%
Bank and Trust
3.01%
Pension Fund
1.52%
Individual Investor
1.06%
Sovereign Wealth Fund
1.04%
Insurance Company
0.08%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
1367
52.25M
129.09%
+28.56K
2025Q3
1413
52.22M
129.54%
+64.86K
2025Q2
1411
52.12M
127.74%
-2.86M
2025Q1
1414
54.69M
123.53%
-5.98M
2024Q4
1410
54.25M
114.75%
+1.17M
2024Q3
1372
53.38M
114.53%
-33.66K
2024Q2
1378
53.46M
111.45%
+347.48K
2024Q1
1371
53.18M
111.09%
-4.05M
2023Q4
1405
52.96M
112.24%
-202.82K
2023Q3
1421
52.99M
111.08%
+631.82K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
5.80M
11.79%
-293.30K
-4.81%
Jun 30, 2025
Wellington Management Company, LLP
3.77M
7.66%
-517.21K
-12.07%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.75M
5.59%
-156.85K
-5.39%
Jun 30, 2025
Allspring Global Investments, LLC
2.29M
4.66%
+516.52K
+29.11%
Jun 30, 2025
State Street Investment Management (US)
1.86M
3.78%
-43.84K
-2.30%
Jun 30, 2025
Ariel Investments, LLC
1.42M
2.88%
+314.57K
+28.58%
Jun 30, 2025
Harris Associates L.P.
1.16M
2.36%
+1.16M
--
Jun 30, 2025
Geode Capital Management, L.L.C.
1.23M
2.5%
-31.43K
-2.49%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.01M
2.05%
+148.44K
+17.22%
Jun 30, 2025
Invesco Capital Management LLC
1.09M
2.22%
+110.27K
+11.23%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Invesco S&P 500 Equal Weight Health Care ETF
1.92%
Schwab Ariel Opportunities ETF
1.82%
iShares Health Innovation Active ETF
1.74%
First Trust NASDAQ Pharmaceuticals ETF
1.71%
ROBO Global Healthcare Technology & Innovation ETF
1.69%
VanEck Biotech ETF
1.44%
Franklin Genomic Advancements ETF
1.42%
WisdomTree US Value Fund
1.15%
Invesco S&P 500 High Beta ETF
1.14%
Pacer Lunt Large Cap Alternator ETF
0.97%
Ver más
Invesco S&P 500 Equal Weight Health Care ETF
Proporción1.92%
Schwab Ariel Opportunities ETF
Proporción1.82%
iShares Health Innovation Active ETF
Proporción1.74%
First Trust NASDAQ Pharmaceuticals ETF
Proporción1.71%
ROBO Global Healthcare Technology & Innovation ETF
Proporción1.69%
VanEck Biotech ETF
Proporción1.44%
Franklin Genomic Advancements ETF
Proporción1.42%
WisdomTree US Value Fund
Proporción1.15%
Invesco S&P 500 High Beta ETF
Proporción1.14%
Pacer Lunt Large Cap Alternator ETF
Proporción0.97%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Charles River Laboratories International Inc?
Los cinco principales accionistas de Charles River Laboratories International Inc son:
The Vanguard Group, Inc. posee 5.80M acciones, lo que representa el 11.79% del total de acciones.
Wellington Management Company, LLP posee 3.77M acciones, lo que representa el 7.66% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 2.75M acciones, lo que representa el 5.59% del total de acciones.
Allspring Global Investments, LLC posee 2.29M acciones, lo que representa el 4.66% del total de acciones.
State Street Investment Management (US) posee 1.86M acciones, lo que representa el 3.78% del total de acciones.
The Vanguard Group, Inc. posee 5.80M acciones, lo que representa el 11.79% del total de acciones.
Wellington Management Company, LLP posee 3.77M acciones, lo que representa el 7.66% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 2.75M acciones, lo que representa el 5.59% del total de acciones.
Allspring Global Investments, LLC posee 2.29M acciones, lo que representa el 4.66% del total de acciones.
State Street Investment Management (US) posee 1.86M acciones, lo que representa el 3.78% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Charles River Laboratories International Inc?
Los tres principales tipos de accionista de Charles River Laboratories International Inc son:
The Vanguard Group, Inc.
Wellington Management Company, LLP
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Wellington Management Company, LLP
BlackRock Institutional Trust Company, N.A.
¿Cuántas instituciones poseen acciones de Charles River Laboratories International Inc (CRL)?
A fecha de 2025Q4, 1367 instituciones poseen acciones de Charles River Laboratories International Inc, con un valor de mercado combinado de aproximadamente 52.25M, lo que representa el 129.09% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en -0.45%.
¿Cuál es la mayor fuente de ganancias de Charles River Laboratories International Inc?
El FY2025Q2, el segmento empresarial DSA generó la ganancia más alta para Charles River Laboratories International Inc, ascendiendo a 618.03M y representando el 59.88% de la ganancia total.
